Jafron Biomedical Co Ltd (300529) — Working Capital to Net Assets Ratio
Jafron Biomedical Co Ltd (300529) has a Working Capital to Net Assets ratio of 72.6% as of March 2026. Working capital of CN¥2.69 Billion (current assets of CN¥3.03 Billion minus current liabilities of CN¥348.56 Million) is measured against net assets of CN¥3.70 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Jafron Biomedical Co Ltd to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jafron Biomedical Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Jafron Biomedical Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 72.6%, reflecting working capital of CN¥2.69 Billion against net assets of CN¥3.70 Billion CNY. See 300529 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Jafron Biomedical Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jafron Biomedical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300529 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 69.6% | CN¥2.42 Billion | CN¥3.47 Billion | CN¥2.92 Billion | CN¥502.10 Million | ▲ +9.1 pp |
| 2024 | 60.5% | CN¥2.02 Billion | CN¥3.33 Billion | CN¥2.78 Billion | CN¥766.79 Million | ▼ -18.3 pp |
| 2023 | 78.7% | CN¥2.48 Billion | CN¥3.15 Billion | CN¥3.31 Billion | CN¥829.42 Million | ▲ +7.0 pp |
| 2022 | 71.7% | CN¥2.58 Billion | CN¥3.59 Billion | CN¥3.29 Billion | CN¥717.18 Million | ▼ -7.1 pp |
| 2021 | 78.9% | CN¥2.67 Billion | CN¥3.38 Billion | CN¥3.06 Billion | CN¥386.26 Million | ▲ +20.5 pp |
| 2020 | 58.4% | CN¥1.66 Billion | CN¥2.83 Billion | CN¥1.99 Billion | CN¥330.82 Million | ▼ -1.3 pp |
| 2019 | 59.8% | CN¥1.30 Billion | CN¥2.17 Billion | CN¥1.56 Billion | CN¥262.63 Million | ▲ +0.2 pp |
| 2018 | 59.6% | CN¥1.03 Billion | CN¥1.72 Billion | CN¥1.31 Billion | CN¥278.90 Million | ▼ -9.4 pp |
| 2017 | 69.0% | CN¥960.82 Million | CN¥1.39 Billion | CN¥1.23 Billion | CN¥269.84 Million | ▼ -8.2 pp |
| 2016 | 77.3% | CN¥914.91 Million | CN¥1.18 Billion | CN¥999.20 Million | CN¥84.29 Million | ▲ +22.1 pp |
| 2015 | 55.1% | CN¥311.03 Million | CN¥564.06 Million | CN¥400.19 Million | CN¥89.16 Million | ▼ -1.7 pp |
| 2014 | 56.9% | CN¥257.30 Million | CN¥452.42 Million | CN¥310.92 Million | CN¥53.62 Million | ▼ -8.0 pp |
| 2013 | 64.9% | CN¥246.63 Million | CN¥380.12 Million | CN¥299.92 Million | CN¥53.29 Million | ▼ -9.9 pp |
| 2012 | 74.8% | CN¥217.62 Million | CN¥290.84 Million | CN¥254.58 Million | CN¥36.95 Million | ▼ -9.7 pp |
| 2011 | 84.6% | CN¥182.30 Million | CN¥215.57 Million | CN¥210.83 Million | CN¥28.53 Million | — |